Literature DB >> 14769009

Italian drug policy: ethical aims of essential assistance levels.

Alessandra Bernardi1, Renzo Pegoraro.   

Abstract

In 2001 the Italian Government defined Essential Assistance Levels (LEA), which can be considered as an important step forward in the health care system. The Italian health care system would provide payment of essential and uniform aid services in order to safeguard many values such as human dignity, personal health, equal assistance and good health practices. The Ministry of Health has worked to rationalize the National Formulary and to define evaluation methods for drugs in order to choose what to reimburse without penalizing the rights of the individual and society. This paper describes how this job of rationalization was done and tries to illustrate the choices made in Italy by the use of two meaningful examples (statins and rivastigmine).

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Substances:

Year:  2003        PMID: 14769009     DOI: 10.1023/B:HCAN.0000010056.05684.22

Source DB:  PubMed          Journal:  Health Care Anal        ISSN: 1065-3058


  11 in total

Review 1.  An economic perspective on Alzheimer's disease.

Authors:  M Trabucchi
Journal:  J Geriatr Psychiatry Neurol       Date:  1999       Impact factor: 2.680

2.  Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price.

Authors:  V Atella
Journal:  Health Policy       Date:  2000-01       Impact factor: 2.980

3.  Capitation and risk adjustment in health care.

Authors:  N Rice; P C Smith
Journal:  Health Care Manag Sci       Date:  2000-02

4.  The new pharmaceutical policy in Italy.

Authors:  G Fattore; C Jommi
Journal:  Health Policy       Date:  1998-10       Impact factor: 2.980

5.  Do pharmaceutical prices respond to potential patient out-of-pocket expenses?

Authors:  Nina Pavenik
Journal:  Rand J Econ       Date:  2002

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Drug reimbursement: indicators of inappropriate resource allocation.

Authors:  Bernard Bégaud; Ulf Bergman; Hans-Georg Eichler; Hubert G M Leufkens; Peter J Meier
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  1 in total

1.  Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.

Authors:  Martina Bonifazi; Marta Rossi; Lorenzo Moja; Vincenzo Davide Scigliano; Matteo Franchi; Carlo La Vecchia; Carlo Zocchetti; Eva Negri
Journal:  Oncologist       Date:  2011-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.